Palvella Therapeutics (PVLA) is a clinical-stage biopharma stock with no revenue or FDA pipeline, but shares are up 508% over the past year. Trading at a new 2-year high, PVLA has strong technical indicators, making it suitable for traders due to its extreme volatility. Valued at $1.11 billion, Palvella focuses on developing therapies for rare genetic skin diseases. Technical indicators show PVLA hitting a 2-year high of $103, with a 100% “Buy” opinion from Barchart. Analysts have mixed opinions, with Wall Street bullish but individual investors cautious. PVLA is for speculators, not investors, driven by ETF momentum.

Read more at Barchart: The Short-Sellers May Be Right About This Red-Hot Pharma Stock